|
Commitments and Contingencies (Details Textual) (USD $)
|
1 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2012
|
Jun. 30, 2012
UFRF [Member]
|
Jun. 30, 2012
Intrexon [Member]
|
Jun. 30, 2012
Intrexon [Member]
Filing of First Investigational New Drug Application [Member]
|
Jun. 30, 2012
Intrexon [Member]
Filing of First New Drug Application [Member]
|
Jun. 30, 2012
Intrexon [Member]
First Regulatory Approval of Oragenics Product [Member]
|
Jun. 30, 2012
Intrexon [Member]
Clinical study Phase 2 [Member]
|
Jun. 30, 2012
Intrexon [Member]
Clinical study Phase 3 [Member]
|
|
| Commitments and Contingencies (Textual) [Abstract] | ||||||||
| Common stock issued | 6,285,619 | 599,940 | 4,392,425 | |||||
| Company obligation to pay from percentage of selling price of product | 5.00% | |||||||
| Company obligation to pay from all revenue receive from sublicenses | 20.00% | |||||||
| License agreement amount | $ 50,000 | |||||||
| Minimum Royalty payment to UFRF | 100,000 | |||||||
| Royalty payment to UFRF in installment | 25,000 | |||||||
| Company obligated to spend on research and development, regulatory | $ 1,000,000 | |||||||
| Company will pay on Quarterly basis out of gross profit | 25.00% | |||||||
| Company obligation to pay from all revenue receive from sublicences | 50.00% | |||||||
| Termination Notice Period | 90 days | |||||||
| Channel Agreement | 18 months | |||||||
| Percentage of base shares equal to number of shares for common stock | 1.00% | 2.50% | 3.00% | 1.50% | 2.00% | |||
| Maximum percentage of primary investment securities to investment of shares issued | 10.00% | |||||||